Cogent Biosciences Inc (COGT NASDAQ) stock market data APIs
$12.3751
0.19(1.5%)
as of July 18, 2025
Try our APIs with
free plan!
Cogent Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Prev. Close
12.3751
Open
12.567
High
12.8496
Low
12.211
52 wk Range
3.72-12.95
Market Cap
1 741 M
Shares Outstanding
139 M
EPS
-0.5249
Beta
0.226
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cogent Biosciences Inc data using free add-ons & libraries
Get Cogent Biosciences Inc Fundamental Data
Cogent Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -285 976 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.5771
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cogent Biosciences Inc News
New
Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors
Think Investments filed an initial 13D regarding its stake in the provider of outsourced digital services, shifting to the stance of an activist investor from previous disclosures in a passive 13G. In...
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz
[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that ...
Cogent Biosciences stock hits 52-week high at 12.66 USD
Cogent Biosciences Inc. stock has reached a new 52-week high, hitting a price of 12.66 USD. According to InvestingPro data, the stock has shown remarkable momentum with a 51.9% gain over the past six ...
Citi raises Cogent stock price target to $22 on bezuclastinib potential
Investing.com - Citi has raised its price target on Cogent (NASDAQ:COGT) to $22.00 from $15.00 while maintaining a Buy rating, citing positive results from the company’s SUMMIT trial. The new target...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
